CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo plus cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients ( pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.